Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Net Margin
Saniona AB

-328.8%
Current
-1 825%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-328.8%
=
Net Income
-81.8m
/
Revenue
24.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
DK
Saniona AB
STO:SANION
903.3m SEK
-329%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
Country DK
Market Cap 903.3m SEK
Net Margin
-329%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.7B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-328.8%
=
Net Income
-81.8m
/
Revenue
24.9m
What is the Net Margin of Saniona AB?

Based on Saniona AB's most recent financial statements, the company has Net Margin of -328.8%.